Nuclera
PrivateLast Round
Series C
Extension
Jan 13, 2026
Est. Valuation
$17.09M
Total Funding Raised
$211.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nuclera is a biotechnology company that develops automated protein prototyping systems to accelerate drug discovery workflows.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, 3D Printing
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuclera Comparables
Compare Nuclera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biotage AB | 74% | |
| Thermo Fisher Scientific Inc. | 71% | |
| Evonetix | 69% |
Nuclera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 13, 2026 | ||||
| Series C | Oct 16, 2024 | ||||
| Grant | Jun 6, 2024 | ||||
| Grant | Dec 6, 2023 | ||||
| Series B Extension | Jul 6, 2022 | ||||
Series B | Feb 2, 2022 |
Key People
Founding team and executive leadership
Nuclera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Amadeus Capital Partners | Series B |
| Verve Ventures | Series B Extension, Series C, Series C Extension, Series B |
| G. K. Goh Holdings Pte. Ltd. | Series C Extension, Series B, Series C |
| Future Planet Capital Regional | Series B |
| RT Ventures | Series A |
| Patient Square Capital | Series C, Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 30, 2026
Launched nanodisc panel for GPCR screening and scale-up.
- Mar 29, 2026
Received an award at the One Nucleus Awards 2026.
Recent news
Latest coverage and updates
- hiresSep 24, 2026
Nuclera hires Carl as CEO.
- hiresSep 22, 2026
Nuclera hired Carl Raimond as Chief Executive Officer on Sep 22nd '26.
Nuclera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nuclera's valuation, stock price, and market status.
Is Nuclera Nucleics a public or private company?
Nuclera Nucleics is a private company.
What is the current stock price of Nuclera Nucleics?
Nuclera Nucleics is a private company with no public stock price. No recent secondary market data is available.
How much is Nuclera Nucleics worth (valuation)?
Nuclera Nucleics's valuation is estimated at $17.1M based on funding round data.
Can I buy Nuclera Nucleics stock?
Nuclera Nucleics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nuclera Nucleics's last funding round?
Nuclera Nucleics's most recent funding round was Series C on November 1, 2018.
Who are the main investors in Nuclera Nucleics?
Key investors in Nuclera Nucleics include RT Partners, Elevage Medical Technologies.
Will Nuclera Nucleics IPO soon?
No public IPO plans have been announced for Nuclera Nucleics.
How can I track Nuclera Nucleics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nuclera Nucleics's secondary market activity and sign up for updates.